The Malaria Vectored Vaccines Consortium (MVVC)

Dr Nicola Viebig & Dr Odile Leroy
Project Leader & Coordinator MVVC
Seventh EDCTP Forum
Berlin, 01 July 2014
Introduction

Integrating capacity building and networking in the design and conduct of phase I and II clinical trials of viral vectored malaria vaccine candidates in East and West African children and infants
Project & Partners

Five year project: 2009 – 2014
Total budget: ~ €9.5m
8 partners
MVVC Structure

- Work Package 1: Project Management
- Work Package 2: Clinical Trials
- Work Package 3: Capacity Building
- Work Package 4: Networking
Project Management

Seventh EDCTP Forum 2014
Achievements – Project Management

- A well-managed consortium with the objectives met within the expected timelines

- Set-up of procedures and the operation decision making organs within the project

- Successful reporting to and communication with EDCTP
Clinical Trials
Heterologous Prime boost with ChAd63/MVA expressing ME-TRAP

This vaccine regimen showed significant efficacy in UK vaccinees following sporozoite challenge.

Next step is to assess the efficacy in the target population: African infants.
Healthy male adults

KEMRI, Kenya (VAC040) & MRC, The Gambia (VAC041)

Results:
- Well tolerated (all AEs were mild)
- Large T-cell responses which were greater in subjects receiving the higher dose
  - Kimani et al, Mol Ther. 2014

Healthy 2-6 years

MRC, The Gambia (VAC041)

Results:
- Well tolerated
- High T-cell responses

Healthy infants

MRC, The Gambia (VAC042)

Results:
- Well tolerated
- High T-cell responses
### Healthy male adults

**KEMRI, Kenya (VAC046) & UCAD, Senegal (VAC041)**

**Results:**
- KEMRI, Kenya (VAC046)
- UCAD, Senegal (VAC047)
- Studies presented by Dr Badara Cissé: **MO.13**

### Healthy infants

**CNRFP, Burkina Faso (VAC050)**

**Results:**
- 700 infants aged 5 – 17 months recruited and vaccinated
- Study presented by Dr Alfred Tiono (CNRFP): **MO.12**
Achievements – Capacity Building

• Site infrastructure and laboratory equipment upgrade completed

Banfora, Burkina Faso (CNRFP)  

Keur Socé, Senegal (UCAD)

• Two baseline epidemiological studies at UCAD and CNRFP were conducted. Recruitment targets met. (MO.11, Dr Issa Nebie)
Achievements
Long-term training

MSc Students

- Jean-Baptiste Bibié Yaro (CNRFP)
- Massamba Syll (UCAD)
- Ya Jankey Jagne (MRC)

All MSc students completed training

PhD Students

- David Tiga Kangoye (CNRFP)
- Mahamadou Mansour Ndiath (UCAD)
- Muhammed Afolabi (MRC) (CO.31)

The training of the PhD students is on-going.

Postdoc

- Francis Maina Ndung’u (KEMRI)

Training completed
## Achievements

### Short-term training

<table>
<thead>
<tr>
<th>Topic</th>
</tr>
</thead>
<tbody>
<tr>
<td>Basic &amp; Applying GCP</td>
</tr>
<tr>
<td>Protocol Development</td>
</tr>
<tr>
<td>Data Management</td>
</tr>
<tr>
<td>Cell-Mediated Immunity Training</td>
</tr>
<tr>
<td>PhD students Workshop on Statistical Tools</td>
</tr>
<tr>
<td>Publication Writing</td>
</tr>
<tr>
<td>Finance Management</td>
</tr>
</tbody>
</table>
Networking
Achievements – Networking

• Well established and sustainable network
• Successful partnership to obtain grants:
  – Successful EDCTP joint application awarded to the eICT project
    • Kintampo Health Research Centre
    • + three MVVC partners (KEMRI/CNRFP/EVI)
  – EDCTP strategic primer grant awarded to the MVVC 2 project
    • MVVC partners
    • + Kintampo Health Research Centre
    • + Novartis Vaccines and Diagnostics
Presentations & Publications

• 11 publications in peer-reviewed journals
• **Presentations** at several international conferences: ASTMH Meeting, EDCTP Forum, EVI Rendez-Vous, DTG Meeting, Malaria Vaccines for the World, MIM PAN African Malaria Conference
Acknowledgements

- All partners
- Subjects in Kenya, The Gambia, Senegal and Burkina Faso
- EVI team: Odile Leroy, Ines Petersen, Flavia D‘Alessio, Sten Larsen, Nathalie Imbault
Thank you for your attention

www.malariavvconsortium.eu
nicola.viebig@euvaccine.eu
odile.leroy@euvaccine.eu
Publications

- **Imoukhuede EB.** Vaccine Ventures (International Innovation, Healthcare, May 2012)
- **Bakshi S, Imoukhuede EB.** Malaria Vectored Vaccines Consortium. (Human Vaccines, Jun 2010)
- **Additional manuscripts are submitted or in preparation**
Presentations

• The MVVC activities were presented e.g. at the:
  – ASTMH Meeting 2011, 2012 & 2013
  – EDCTP Forum 2011 & 2014
  – DTG Meeting 2012, Malaria Vaccines for the World 2013 Meeting and the 6th MIM PAN African Malaria Conference